Fujifilm Diosynth Biotechnologies, maker of the Noravax COVID-19 vaccine, is doubling down on its manufacturing presence in Texas with a $300 million expansion of its facilities in College Station.
Fujifilm Diosynth Biotechnologies, maker of the Noravax COVID-19 vaccine, is doubling down on its manufacturing presence in Texas with a $300 million expansion of its facilities in College Station.
Watch the video to learn how you can access industry leading CRE news and the data analytics you need to drive success.
This news story is available exclusively to CoStar subscribers.
Ready to Learn More?
Sign Up For a Personalized Demo.
Sign Up For a Demo To Learn More.
Already A Subscriber? Sign In